Shuttle Pharmaceuticals Holdings, Inc.
SHPH · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.00 | -0.08 | -0.30 |
| FCF Yield | -33.13% | -79.03% | -6.37% | -3.07% |
| EV / EBITDA | -2.87 | -0.04 | -11.93 | -60.40 |
| Quality | ||||
| ROIC | -109.51% | -88.85% | -66.89% | -93.15% |
| Gross Margin | 0.00% | 0.00% | 0.00% | -31.25% |
| Cash Conversion Ratio | 1.12 | 0.91 | 0.83 | 1.68 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 21.71% | -32.77% | 6.07% | -34.60% |
| Safety | ||||
| Net Debt / EBITDA | 0.63 | 1.11 | 1.12 | 0.52 |
| Interest Coverage | 3,144.16 | -179.85 | -247.38 | -11.16 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -80,079.02 | -18,682.67 |